| abstract |
The present invention relates to compounds of general formula (I) or their pharmaceutically acceptable salts or prodrugs, and to pharmaceutical compositions thereof. In the general formula (I), the main meanings of the asymmetric meanings are: B is a nitro-genome or -CH; A is substituted alkyl, cycloalkyl or cycloalkylalkylfiltrate; Q is a substituted substituted alkylene tube which is substituted with amino, phenyl, phenyl, phenyl, substituted phenyl, phenyl, phenyl, carbamoyl, carbamoyl, oxy, carbamoyl, carbamoyl, oxy, 5-, or a 6-membered, mammalian ring containing 1-2 hymns selected from the group consisting of xenogene, nitrogen and sulfur; Z is as defined by the following: carbamoyl; K is a bond, an alkylene, thioalkylene, or an alkoxyalkylene coat, optionally substituted; M is -Ar, -Ar1-V-Ar2, -Ar1-S-Ar2, or -Ar1-O-Ar2, respectively, wherein Ar, Ar1, and Ar2 are each independently substituted, partially saturated, fully saturated or fully \ t an unsaturated 5-8 membered ring containing 1-4 heterocyclic rings independently selected from the group consisting of xylene, sulfur and nitrogens, or a bicyclic ring consisting of two stone-partially partially saturated, fully saturated, unsaturated 5- or 6-membered rings which independently, in the given case, they contain 1-4 heteroatoms independently selected from the group consisting of nitrogen, sulfur, and xenogene, V is a compound bond or substituted alkylene coat in the case of addition. Compounds have prostaglandin agonist activity. The present invention also encompasses a stone-quinone pharmaceutical composition for treating cervical spasm. ŕ |